{
    "clinical_study": {
        "@rank": "18250", 
        "acronym": "PRONOVA", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Identical olive oil capsules"
            }, 
            {
                "arm_group_label": "Omega-3", 
                "arm_group_type": "Experimental", 
                "description": "4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether the marine omega-3 fatty acids can attenuate\n      inflammatory responses to endotoxin challenge."
        }, 
        "brief_title": "Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Responses", 
        "condition_browse": {
            "mesh_term": "Inflammation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men between the ages of 20 and 45.\n\n          2. BMI \u226520 and \u226430\n\n          3. Participants who are able to give written informed consent and willing to comply with\n             all study-related procedures.\n\n          4. Any race or ethnic background is acceptable\n\n          5. Non-smoking\n\n        The specific exclusion criteria are:\n\n          1. Previous history of vasovagal reactions or unprovoked fainting (I.e. fainting as a\n             result of prolonged standing, exercise)\n\n          2. Resting heart rate < 55 bpm\n\n          3. History of atherosclerotic cardiovascular disease, including coronary disease,\n             cerebrovascular disease, or peripheral vascular disease\n\n          4. History of diabetes mellitus (and/or a fasting glucose >126 mg/dL at screening)\n\n          5. Chronic anti-inflammatory medication use or treatment with aspirin, NSAIDs, COX-2\n             inhibitors; steroids or any immunomodulatory therapy 2 weeks prior to the screening\n             visit\n\n          6. Self-reported history of allergy to fish\n\n          7. History of a non-skin malignancy within the previous 5 years\n\n          8. Renal insufficiency as defined by creatinine outside of lab defined normal range at\n             Screening Visit\n\n          9. History of liver disease or abnormal LFTs (AST, ALT, Alk. Phos., GGT > 1.5x ULN;\n             bilirubin > 2x ULN) at Screening Visit\n\n         10. Total white blood cell count less than or equal to 3.0 THO/uL\n\n         11. Hemoglobin less than 11.0 g/dL\n\n         12. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory\n             condition or minor active infection\n\n         13. Self-reported history of HIV positive\n\n         14. Participants who have undergone any organ transplant\n\n         15. Individuals who currently use tobacco products or have done so in the previous 30\n             days.\n\n         16. Participants who are unwilling to discontinue use of nutritional supplements, herbs\n             or vitamins unless approved by study staff.\n\n         17. Participants who are unwilling to eliminate omega-3 fatty acid (EPA + DHA)\n             supplements and/or fortified food, or have a usual intake of high omega-3 fish (tuna\n             and other non-fried fish) > 2 servings per week\n\n         18. Elevated blood pressure (BP > 159/99) or use of any anti-hypertensive medications.\n\n         19. Latex allergy\n\n         20. Unwillingness to refrain from blood donation for 2 months prior to and following\n             endotoxin administration\n\n         21. Any medical condition or abnormal laboratory value that is judged clinically\n             significant by an investigator\n\n         22. Inability to take study capsules\n\n         23. History of severe, repeated headaches\n\n         24. History of migraine\n\n         25. Medical condition that causes severe nausea or vomiting\n\n         26. Low resting blood pressure (SBP < 90 mmHg)\n\n         27. History of atrial fibrillation/flutter\n\n         28. Abnormal coagulation parameters (platelet count, prothrombin time with INR),\n             documented coagulation abnormality, or use of anticoagulant medication\n\n         29. High LDL-C (> or = 160 mg/dL)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813110", 
            "org_study_id": "PRONOVA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega-3", 
                "description": "4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks", 
                "intervention_name": "4 g prescription omega-3 concentrate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lovaza", 
                    "Omacor"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "inflammation", 
            "omega-3", 
            "fish oil"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "University Park", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "16802"
                }, 
                "name": "Penn State University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of a Prescription Omega-3 Fatty Acid Concentrate in a Placebo-controlled Trial of Human Endotoxemia", 
        "overall_contact": {
            "email": "aus164@psu.edu", 
            "last_name": "Ann C. Skulas-Ray, PhD", 
            "phone": "814-863-8056"
        }, 
        "overall_contact_backup": {
            "email": "jas58@psu.edu", 
            "last_name": "Jennifer A. Fleming, MS, RD", 
            "phone": "814-863-8056"
        }, 
        "overall_official": {
            "affiliation": "Penn State University", 
            "last_name": "Gordon Jensen, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in blood levels of CRP at 24 hours post endotoxin administration", 
            "measure": "Change in C reactive protein (CRP)", 
            "safety_issue": "No", 
            "time_frame": "24 hours post endotoxin administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813110"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Penn State University", 
            "investigator_full_name": "Penny Kris-Etherton", 
            "investigator_title": "Distinguished Professor of Nutrition", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Changes in plasma levels of prostaglandin J3 resulting from omega-3 supplementation and induced inflammation", 
            "measure": "Prostaglandin J3", 
            "safety_issue": "No", 
            "time_frame": "7 days post endotoxin challenge"
        }, 
        "source": "Penn State University", 
        "sponsors": {
            "collaborator": {
                "agency": "Pronova BioPharma", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Penn State University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}